抗精神病药相关DRESS综合征:WHO药物警戒数据库个例安全性报告分析
基于WHO VigiBase数据库的病例/非病例研究,分析19种抗精神病药相关的DRESS综合征报告。抗精神病药整体与所有其他药物的ROR为1.0(95%CI 0.9-1.1),但氯氮平、氰美马嗪和氯丙嗪呈现 disproportionate reporting,且严重病例中合并抗惊厥药和多种抗精神病药的比例更高。
要点
- 氯氮平、氰美马嗪和氯丙嗪报告DRESS的ROR分别为2.3、2.3和1.5,高于预期。
- 严重病例中35.7%合并抗惊厥药,25%合并多种抗精神病药,比例显著高于非严重病例。
- 致死性病例占10.7%,临床需警惕抗精神病药相关DRESS的严重性。
核心结论
- 除氯氮平外,氯丙嗪和氰美马嗪(共享芳香杂多环分子结构)也呈现高于预期的DRESS报告。
研究设计与样本
- 基于WHO全球自发报告数据库VigiBase的病例/非病例研究,采用不成比例分析。
- 共分析19种抗精神病药相关的1534份DRESS综合征个例安全性报告。
主要发现
- 抗精神病药整体与所有其他药物比较的ROR为1.0(95%CI 0.9-1.1)。
- 氯氮平ROR 2.3(95%CI 2.1-2.5),IC 1.2(95%CI 1.1-1.3)。
- 氰美马嗪ROR 2.3(95%CI 1.5-3.5),IC 1.2(95%CI 0.5-1.7)。
- 氯丙嗪ROR 1.5(95%CI 1.1-2.1),IC 0.6(95%CI 0.1-1.0)。
- 严重病例中35.7%合并抗惊厥药,25%合并多种抗精神病药,非严重病例中为8.6%(p=0.03);致死性病例164例(10.7%)。
临床怎么用
- 临床处方抗精神病药时应警惕DRESS综合征,尤其使用氯氮平、氯丙嗪和氰美马嗪时。
- 对合并使用抗惊厥药或多种抗精神病药的患者应加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is gaining attention in pharmacovigilance, but its association with antipsychotics, other than clozapine, is still unclear. METHODS: We conducted a case/non-case study with disproportionality analysis based on the World Health Organization (WHO) global spontaneous reporting database, VigiBase®. We analyzed individual case safety reports of DRESS syndrome related to antipsychotics compared to (1) all other medications in VigiBase®, (2) carbamazepine (a known positive control), and (3) within classes (typical/atypical) of antipsychotics. We calculated reporting odds ratio (ROR) and Bayesian information component (IC), with 95% confidence intervals (CIs). Disproportionate reporting was prioritized based on clinical importance, according to predefined criteria. Additionally, we compared characteristics of patients reporting with serious/non-serious reactions. RESULTS: A total of 1534 reports describing DRESS syndrome for 19 antipsychotics were identified. The ROR for antipsychotics as a class as compared to all other medications was 1.0 (95% CI 0.9-1.1). We found disproportionate reporting for clozapine (ROR 2.3, 95% CI 2.1-2.5; IC 1.2, 95% CI 1.1-1.3), cyamemazine (ROR 2.3, 95% CI 1.5-3.5; IC 1.2, 95% CI 0.5-1.7), and chlorpromazine (ROR 1.5, 95% CI 1.1-2.1; IC 0.6, 95% CI 0.1-1.0). We found 35.7% of cases with co-reported anticonvulsants, and 25% with multiple concurrent antipsychotics in serious compared to 8.6% in non-serious cases (p = 0.03). Fatal cases were 164 (10.7%). CONCLUSIONS: Apart from the expected association with clozapine, chlorpromazine and cyamemazine (sharing an aromatic heteropolycyclic molecular structure) emerged with a higher-than-expected reporting of DRESS. Better knowledge of the antipsychotic-related DRESS syndrome should increase clinicians' awareness leading to safer prescribing of antipsychotics.
引用
- de Filippis R, Kane JM, Arzenton E, et al. Antipsychotic-Related DRESS Syndrome: Analysis of Individual Case Safety Reports of the WHO Pharmacovigilance Database. Drug Saf. 2024. PMID: 38722481. doi:10.1007/s40264-024-01431-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。